Exela Pharma Company Profile
✉ Email this page to a colleague
What is the competitive landscape for EXELA PHARMA, and what generic alternatives to EXELA PHARMA drugs are available?
EXELA PHARMA has twenty-three approved drugs.
There are sixteen US patents protecting EXELA PHARMA drugs.
Summary for Exela Pharma
US Patents: | 16 |
Tradenames: | 20 |
Ingredients: | 20 |
NDAs: | 23 |
Patent Litigation for Exela Pharma: | See patent lawsuits for Exela Pharma |
Drugs and US Patents for Exela Pharma
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Exela Pharma | CAFFEINE CITRATE | caffeine citrate | SOLUTION;ORAL | 077304-001 | Sep 21, 2006 | AA | RX | No | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Exela Pharma | POTASSIUM ACETATE | potassium acetate | INJECTABLE;INJECTION | 206203-001 | Dec 29, 2015 | AP | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Exela Pharma | VAZCULEP | phenylephrine hydrochloride | SOLUTION;INTRAVENOUS | 204300-002 | Jun 27, 2014 | AP1 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Exela Pharma | POTASSIUM ACETATE | potassium acetate | INJECTABLE;INJECTION | 212692-001 | Oct 20, 2021 | AP | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Exela Pharma | BLOXIVERZ | neostigmine methylsulfate | SOLUTION;INTRAVENOUS | 204078-001 | May 31, 2013 | AP | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Exela Pharma | SODIUM BICARBONATE | sodium bicarbonate | INJECTABLE;INJECTION | 211091-001 | Jun 20, 2019 | AP | RX | No | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Similar Applicant Names
Here is a list of applicants with similar names.